REFERENCES
1. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
2. Dariushnia SR, Haskal ZJ, Midia M, et al. ; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts. J Vasc Interv Radiol 2016;27:1-7.
3. Lucatelli P, Burrel M, Guiu B, et al. CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67.
4. Kuo YC, Kohi MP, Naeger DM, et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2013;36:1336-43.
5. Padia SA, Chewning RH, Kogut MJ, et al. Outcomes of locoregional tumor therapy for patients with hepatocellular carcinoma and transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol 2015;38:913-21.
6. Wang Z, Zhang H, Zhao H, et al. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol 2014;20:487-91.
7. Padia SA, Shivaram G, Bastawrous S, et al. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. J Vasc Interv Radiol 2013;24:301-6.
8. Odisio BC, Ashton A, Yan Y, et al. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile. J Vasc Interv Radiol 2015;26:965-71.
9. de Baere T, Guiu B, Ronot M, et al. Real life prospective evaluation of new drug-eluting platform for chemoembolization of patients with hepatocellular carcinoma: paris registry. Cancers (Basel) 2020;12:3405.
10. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
11. Lucatelli P, Argirò R, De Rubeis G, et al. Polyethylene glycol epirubicin-loaded transcatheter arterial chemoembolization procedures utilizing a combined approach with 100 and 200 μm microspheres: a promising alternative to current standards. J Vasc Interv Radiol 2019;30:305-13.
12. Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015;7:2009-19.
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
14. Lucatelli P, Argirò R, Ginanni Corradini S, et al. Comparison of image quality and diagnostic performance of cone-beam ct during drug-eluting embolic transarterial chemoembolization and multidetector CT in the detection of hepatocellular carcinoma. J Vasc Interv Radiol 2017;28:978-86.
15. Wang Z, Wang M, Duan F, Song P, Liu F. Bile duct injury after trans- catheter arterial chemoembolization: risk factors and clinical implications. Hepatogastroenterology 2014; 61:947-953.
16. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54.
17. Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 2011;34:37-49.
18. Kang JW, Kim JH, Ko GY, et al. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012;53:545-50.
19. Kohi MP, Fidelman N, Naeger DM, et al. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol 2013;24:68-73.
20. Fan W, Guo J, Zhu B, et al. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol 2021;31:8291-301.
21. Chen X, Qiu ZK, Wang GB, et al. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol 2021;27:671-6.
22. Lammer J, Malagari K, Vogl T, et al. ; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
23. Grosso M, Vignali C, Quaretti P, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008;31:1141-9.
24. Malagari K, Chatzimichael K, Alexopoulou E, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008;31:269-80.
25. Kloeckner R, Weinmann A, Prinz F, et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015;15:465.
26. Liu YS, Lin CY, Chuang MT, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol 2018;18:124.
27. Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
28. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81.
